Citi analyst Geof Meacham lowered the firm’s price target on Avidity Biosciences (RNA) to $72 from $75 and keeps a Buy rating on the shares after the company entered into a merger agreement with Novartis for $72 per share. Citi believes a competitive bid is unlikely.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences downgraded to Market Perform from Strong Buy at Raymond James
- Avidity Biosciences downgraded to Market Perform from Outperform at Bernstein
- Avidity Biosciences downgraded to Neutral from Buy at H.C. Wainwright
- M&A News: Novartis to Acquire Avidity Biosciences in $12B Deal
- Novartis agrees to acquire Avidity for $72 per share in cash